High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer

The T790M ratio to EGFR activating mutation in tumor may correlate with the response to osimertinib, and patients with a higher T790M ratio have a longer treatment history.